We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Genta has announced publication of a new clinical pharmacologic study using
Genasense (oblimersen sodium) injection, the company's lead anticancer compound,
in patients with acute myelocytic leukemia (AML).
Generex Biotechnology has announced that the first patients had received a novel
therapeutic vaccine developed by its wholly owned subsidiary, Antigen Express
as part of the company's Phase I Trial.
Point Therapeutics has achieved the desired tumor response criteria with its
lead compound, talabostat, in its Phase II non-small cell lung cancer (NSCLC)
clinical trial.
A.P. Pharma has initiated a Phase II clinical trial program in cancer patients
with its lead product candidate, APF530, for the prevention of both acute and
delayed chemotherapy-induced nausea and vomiting.
Join FDAnews May 4, to learn concrete steps you can take to protect your
market share and minimize your legal exposure at a 90-minute audioconference
on "Combating Counterfeit Drugs: Keep Illegal Knock-Offs From Knocking
Off Your Earnings." Benefit directly from the expertise of Chris Michie,
a noted attorney and authority on counterfeit drugs, the gray market and illegal
product sales over the internet. On May 24, join FDAnews for "Reduce
Supply Chain Risks: How the FDA Expects You to Manage Outsourced Suppliers."
Learn how to navigate the unexpected liabilities and meet your legal and regulatory
responsibilities from a former top FDA investigator, Martin Browning.
Elite Pharmaceuticals' subsidiary, Elite Laboratories, has filed an investigational
new drug (IND) application for an abuse-resistant oxycodone product utilizing
Elite's proprietary abuse-resistant technology (ART).
ISTA Pharmaceuticals has filed an investigational new drug application with
the FDA to initiate a U.S. Phase III study of a new combination ophthalmic product
containing tobramycin and prednisolone acetate for the treatment of steroid-responsive
inflammatory ocular conditions where risk of bacterial infection exists.
Barr Pharmaceuticals has announced that its subsidiary, Barr Laboratories has
received final approval from the FDA for its generic version of Kos Pharmaceutical's
Niaspan 500-mg, 750-mg and 1,000-mg extended-release tablets (Niacin extended-release
tablets).